Leading Researcher to Deliver Highly Anticipated Keynote Address on Gene Therapy at SITC 2017

MILWAUKEE – On the heels of the U.S. government’s approval of a groundbreaking gene therapy for treating cancer, a leading researcher in the field is set to deliver a highly anticipated keynote address on chimeric antigen receptor T cells, or ‘CAR T’ to kick off the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting.

Stephan Grupp, MD, PhD, the Director of Cancer Immunotherapy and Cell Therapy/Transplant Section at the Children’s Hospital of Pennsylvania in Philadelphia, will deliver his keynote speech, “The CAR T Revolution in Leukemia” on Friday, Nov. 10, 2017 at SITC 2017. The Annual Meeting takes place Nov. 10-12 in National Harbor, Md. Dr. Grupp’s presentation will focus on CAR T, which is a historic, first-of-its-kind gene therapy approved by the U.S. Food and Drug Administration (FDA) on Aug. 30, 2017 that supports the use of tisagenlecleucel in certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL).

“Knowing that incredible advances in CAR T cell therapies were being made by SITC member researchers like Dr. Grupp and Dr. Carl June of the University of Pennsylvania,” said SITC President Lisa H. Butterfield, PhD, “SITC leaders decided in January that a keynote lecture on CAR T cells would really kick off an exciting and productive Annual Meeting for our attendees.”

Preceded by two days of Pre-Conference Programs on Nov. 8-9, which include a basic primer course on tumor immunology and cancer immunotherapy, a grant writing workshop, and other events, the three-day Annual Meeting will feature numerous cutting-edge presentations from leading experts in the field reporting the tremendous progress being made in cancer immunotherapy research.

Paul Sondel, MD, PhD, a professor and renowned researcher at the University of Wisconsin-Madison, will deliver the keynote speech on Saturday, Nov. 11, 2017 entitled, “Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine.” Dr. Sondel is the 2017 recipient of the Richard V. Smalley, MD Memorial Award and Lectureship, the society’s most distinguished award honoring a luminary in the field who has significantly contributed to the advancement of cancer immunotherapy research.

“The 32nd Annual Meeting & Pre-Conference Programs is set to become the most highly attended SITC meeting ever,” Butterfield said. “A major reason why is researchers like Stephan Grupp, who have made their life’s work using the immune system to find a cure for cancer.”

Learn more about SITC 2017 and register to join the society in National Harbor this November by visiting the SITC 2017 Annual Meeting website.

About SITC The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit

KUCCLS (한미 생명과학 협력 컨퍼런스) Nov 2 – 4, 2017

2017년 한미 생명과학 협력컨퍼런스가 여러 후원기관들의 협찬을 받아 11월 2일에서 4일까지 2박3일동안 메릴랜드 락빌에서 개최됩니다.

이번 컨퍼런스에서는 합성 신약과 바이오로직스의 미국내 개발 및 승인과 관련된 미국정부의 인허가과정, 특허출원등 신약개발과 제약 산업 전반에 걸친 주제들을 다루는 프로그램이 준비되고 있읍니다. 원천연구에서 상용화까지의 전과정에 대한 전문가들의 발표와 네트워킹및 협력과제를 만들수있는 시간도 계획되고 있읍니다. 또한 채용 및 커리어에 관한 정보공유기회도 마련되어 있습니다.

아울러 이번 해에는 컨퍼런스 마지막날 NIH-KSA (Korean Scientist Association)와 함께 특별히 The 9th Annual Bioscience and Engineering symposium (ABES)를 공동개최합니다. 많은 성원과 참석을 부탁드립니다. 저희 홈피와 폐북에 계속 준비상황이 업데잇되니 참고하시기 바랍니다.

KUCCLS 2017 organizing committee
KAPAL (Korean- American Professional Association in Life Sciences)

HPI INC (HanAll BioPharma 미국 지사) Recruitment

Company: HPI INC (HanAll BioPharma 미국 지사, 연매출 $80M, market cap $600M)

Location: Rockville, MD

Job Type : Full Time

Salary range: 40,000~55,000

Benefit: Health insurance

Language: English and Korean

Education: biology, pharmacology 관련 분야 학사 학위 이상 취득자



* Scientific analysis by searching articles related to biology, pharmacology, pathophysiology and clinical studies in various disease areas

* Pharmaceutical market research and forecast

* Competitive intelligence activity to monitor other competitors’ developmental status and profile

* Regulatory document review and preparation (US IND and etc)

* Making research collaboration with academic groups in the U.S

* Searching potential business partners

Required skills:


* Analyzing scientific articles (i.e. specific disease, mode of action of specific target, current clinical standard of care, competitive landscape analysis and etc)

* High level of MS Office (Excel, PPT, Word) skills

* High level of data searching, collecting and processing skills


VISA requirement: Work Permit/ Green Card holder

FDA Science Forum Event

The May 31-June 1 FDA Science Forum is a unique opportunity for FDA to demonstrate to the public and our peers in the scientific community the cutting-edge research FDA does to support its mission of protecting and advancing the public health.

The new science and emerging technologies featured in this Forum–from 3D printing and “omics” technologies to whole genome sequencing–are transforming biomedicine and food safety in ways that were unimaginable just two decades ago.

And these technologies are changing the DNA of FDA as well.  The Forum gives us a chance to highlight not only how FDA applies new science to speed safe innovation but how we’re using these new technologies to perform our mission more effectively and to collaborate in exciting new ways with our stakeholders—academia, industry, sister agencies, patients, consumers, and others.